PanGenetics to start Phase I trial of CD40 antagonist antibody
This article was originally published in Scrip
Executive Summary
PanGenetics is to begin a Phase I trial of its first drug candidate – a CD40 antagonist antibody, PG102, for the treatment of psoriatic arthritis.